Guillain-Barre syndrome

A study conducted by researchers at BHU examining the long-term effects of Bharat Biotech’s Covaxin vaccine revealed concerning findings. Out of 926 participants examined, nearly one-third reported adverse events of special interest (AESI), with viral upper respiratory tract infections being the most common complaint. Serious AESI such as stroke and Guillain-Barre syndrome were reported in one percent of individuals. The study, conducted from January 2022 to August 2023, involved 635 adolescents and 291 adults who received the Covaxin vaccine. Common AESI observed in adolescents included skin and subcutaneous disorders, general disorders, and nervous system disorders. In adults, general disorders, musculoskeletal disorders, and nervous system disorders were prevalent. The study highlighted that certain demographics faced higher risks of persistent AESIs. Females, adolescents with pre-vaccination Covid-19, people with underlying health conditions, and those who developed typhoid after vaccination had significantly higher odds of experiencing persistent AESIs. Moreover, adults with pre-existing health conditions had more than double the odds of experiencing AESIs and persistent AESIs, according to the study. Additionally, adults who received three doses of the vaccine and those who received only one dose had higher risks of AESIs compared to those who received two doses of Covaxin. These findings underscore the importance of continued monitoring and assessment of vaccine safety, particularly regarding long-term effects. Further research is needed to better understand the underlying mechanisms and risk factors associated with adverse events following Covaxin vaccination.